(RS)-4-(1-but-3-enyl-pyrrolidine-3-sulfonyl)-phenol | 371240-09-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (RS)-4-(1-but-3-enyl-pyrrolidine-3-sulfonyl)-phenol
• 英文别名: 4-(1-but-3-enylpyrrolidin-3-yl)sulfonylphenol
• CAS: 371240-09-4
• 化学式: C₁₄H₁₉NO₃S
• 分子量: 281.376
• InChiKey: XAJFFXFPNCKVBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (RS)-4-(1-but-3-enyl-pyrrolidine-3-sulfonyl)-phenol 、 3-溴甲基苯 在 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 以47%的产率得到(RS)-4-[1-(4-m-tolyl-butyl)-pyrrolidine-3-sulfonyl]-phenol
  参考文献：
  名称：

  Heterocyclic compounds useful as NMDA receptor selective subtype blockers

  摘要：

  该发明涉及具有以下结构的化合物：其中Ar1是吡啶基或苯基，被羟基、较低烷基、卤素、氨基、硝基、苄氧基或较低烷氧基取代，或者是基团2，其中Z1是一个含有一个或两个异原子（N或O）的五元杂环环，R1是氢、羟基或氧代基，Ar2是吡啶基或苯基，可选择地被羟基、较低烷基、卤素、氨基、硝基、苄氧基或较低烷氧基取代，或者是基团3，其中Z2是一个含有一个或两个异原子（N或O）的五元或六元环，Q是—S—、—S(O)—或—S(O)2—，X是一个键、—CH(OH)—或—(CH2)n—，A是一个键或—(CHR)m—，R是氢、卤素或羟基，如果m为2或3，则彼此独立，Y是—(CR2)m—、—O—、—C═C—、—C≡C—、哌啶-1-基、吡咯啉-1-基或C4-C6环烷基，这些环可选择地被羟基取代，B是一个键、—O—或—(CHR)m—，n为1或2，m为1到3，以及其与药学上可接受的酸盐，但除了A和B同时为键且Y为—CHR—的化合物。这些化合物可用于治疗神经退行性疾病。

  公开号：

  US20010047031A1

文献信息

• PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1278728B1

  公开（公告）日：2004-08-25
• US6451819B2
  申请人：——

  公开号：US6451819B2

  公开（公告）日：2002-09-17
• [EN] PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREAMENT OF NEURODEGENERATIVE DISORDERS<br/>[FR] DERIVES DE LA PYRROLIDINE ET DE LA PIPERIDINE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES NEURODEGENERATIVES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2001081303A1

  公开（公告）日：2001-11-01

  The invention relates to compounds of formula (I) wherein Ar1 is pyridyl or phenyl, substituted by hydroxy, lower alkyl, halogen, amino, nitro, benzyloxy or lower alkoxy-lower alkoxy, or is the group (a) wherein Z1 is a five membered heterocyclic ring, which contains one or two heteroatoms, selected from N or O; R1 is hydrogen, hydroxy or an oxo group; Ar2 is pyridyl or phenyl, optionally substituted by hydroxy, lower alkyl, halogen, amino, nitro, benzyloxy or lower alkoxy-lower alkoxy, or is the group (b) wherein Z2 is a five or six membered ring, which optionally contains one or two heteroatoms, selected from N or O; and Q is -S-, -S(O)- or -S(O)¿2?-; X is a bond, -CH(OH)- or -(CH2)n-; A is a bond or -(CHR)m-; R is hydrogen, halogen or hydroxy, independently from each other if m is 2 or 3; Y is -(CR2)m-, -O-, -C=C-, -C C-, piperidin-1-yl, pyrrolidin-1yl or C4-C6-cycloalkyl, which rings are optionally substituted by hydroxy; B is a bond, -O- or -(CHR)m; n is 1 or 2; and m is 1 to 3 and pharmaceutically acceptable acid addition salts thereof with the exception of compounds, wherein A and B are simultaneously a bond and Y is -CHR-. The compounds may be used in the treatment of neurodegenerative diseases.
• Heterocyclic compounds useful as NMDA receptor selective subtype blockers
  申请人：——

  公开号：US20010047031A1

  公开（公告）日：2001-11-29

  The invention relates to compounds of formula 1 wherein Ar 1 is pyridyl or phenyl, substituted by hydroxy, lower alkyl, halogen, amino, nitro, benzyloxy or lower alkoxy-lower alkoxy, or is the group 2 wherein Z 1 is a five membered heterocyclic ring, which contains one or two heteroatoms, selected from N or O; R 1 is hydrogen, hydroxy or an oxo group; Ar 2 is pyridyl or phenyl, optionally substituted by hydroxy, lower alkyl, halogen, amino, nitro, benzyloxy or lower alkoxy-lower alkoxy, or is the group 3 wherein Z 2 is a five or six membered ring, which optionally contains one or two heteroatoms, selected from N or O; and Q is —S—, —S(O)— or —S(O) 2 —; X is a bond, —CH(OH)— or —(CH 2 ) n —; A is a bond or —(CHR) m —; R is hydrogen, halogen or hydroxy, independently from each other if m is 2 or 3; Y is —(CR 2 ) m —, —O—, —C═C—, —C≡C—, piperidin- 1 -yl, pyrrolidin- 1 yl or C 4 -C 6 -cycloalkyl, which rings are optionally substituted by hydroxy; B is a bond, —O— or —(CHR) m ; n is 1 or 2; and m is 1 to 3 and pharmaceutically acceptable acid addition salts thereof with the exception of compounds, wherein A and B are simultaneously a bond and Y is —CHR—. The compounds may be used in the treatment of neurodegenerative diseases.

  该发明涉及具有以下结构的化合物：其中Ar1是吡啶基或苯基，被羟基、较低烷基、卤素、氨基、硝基、苄氧基或较低烷氧基取代，或者是基团2，其中Z1是一个含有一个或两个异原子（N或O）的五元杂环环，R1是氢、羟基或氧代基，Ar2是吡啶基或苯基，可选择地被羟基、较低烷基、卤素、氨基、硝基、苄氧基或较低烷氧基取代，或者是基团3，其中Z2是一个含有一个或两个异原子（N或O）的五元或六元环，Q是—S—、—S(O)—或—S(O)2—，X是一个键、—CH(OH)—或—(CH2)n—，A是一个键或—(CHR)m—，R是氢、卤素或羟基，如果m为2或3，则彼此独立，Y是—(CR2)m—、—O—、—C═C—、—C≡C—、哌啶-1-基、吡咯啉-1-基或C4-C6环烷基，这些环可选择地被羟基取代，B是一个键、—O—或—(CHR)m—，n为1或2，m为1到3，以及其与药学上可接受的酸盐，但除了A和B同时为键且Y为—CHR—的化合物。这些化合物可用于治疗神经退行性疾病。